Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 493028
                    [Title] => GSK cervical cancer vaccine protects vs most common virus types - trial
                    [Summary] => 
The final analysis of the largest efficacy trial of a cervical cancer vaccine confirmed that GlaxoSmithKline’s vaccine is highly effective not only in protecting against the two most common cervical cancer-causing human papillomavirus (HPV) types, 16 and 18, but also for other most common cervical cancer causing HPV types.
                    [DatePublished] => 2009-08-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

ASIA-PACIFIC AND LATIN AND NORTH AMERICA

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 493028
                    [Title] => GSK cervical cancer vaccine protects vs most common virus types - trial
                    [Summary] => 
The final analysis of the largest efficacy trial of a cervical cancer vaccine confirmed that GlaxoSmithKline’s vaccine is highly effective not only in protecting against the two most common cervical cancer-causing human papillomavirus (HPV) types, 16 and 18, but also for other most common cervical cancer causing HPV types.
                    [DatePublished] => 2009-08-06 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

GSK cervical cancer vaccine protects vs most common virus types - trial

August 6, 2009 - 12:00am

The final analysis of the largest efficacy trial of a cervical cancer vaccine confirmed that GlaxoSmithKline’s vaccine is highly effective not only in protecting against the two most common cervical cancer-causing...

Science and Environment